Home Healthcare Pharmaceuticals Myasthenia Gravis Treatment Market

Myasthenia Gravis Treatment Market Size, Share & Trends Analysis Report By Type (Ocular MG, Congenital MG, Transient Neonatal MG), By Treatment (Medication, Surgery, Autologous Hematopoietic Stem Cell Transplantation (HSCT), Plasmapheresis and Intravenous Immunoglobulin, Others), By End-User (Hospitals, Clinics, Academic Research Institutes, Others) and By Country (U.S., Canada) Forecasts, 2026-2034

Last Updated: July 30, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Myasthenia Gravis Treatment Market, By Type 2022-2034 (USD MILLION/ Units)
    1. Ocular MG 
    2. Congenital MG 
    3. Transient Neonatal MG
  2. Myasthenia Gravis Treatment Market, By Treatment 2022-2034 (USD MILLION/ Units)
    1. Medication 
    2. Surgery 
    3. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
    4. Plasmapheresis and Intravenous Immunoglobulin 
    5. Others
  3. Myasthenia Gravis Treatment Market, By End-User 2022-2034 (USD MILLION/ Units)
    1. Hospitals 
    2. Clinics 
    3. Academic Research Institutes 
    4. Others
  4. Regional Myasthenia Gravis Treatment Market
    1. North America
      1. North America Myasthenia Gravis Treatment Market By Type 2022-2034 (USD MILLION/ Units)
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
      2. North America Myasthenia Gravis Treatment Market By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication 
        2. Surgery 
        3. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        4. Plasmapheresis and Intravenous Immunoglobulin 
        5. Others
      3. North America Myasthenia Gravis Treatment Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals 
        2. Clinics 
        3. Academic Research Institutes 
        4. Others
      4. U.S.
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
        4. Medication 
        5. Surgery 
        6. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        7. Plasmapheresis and Intravenous Immunoglobulin 
        8. Others
        9. Hospitals 
        10. Clinics 
        11. Academic Research Institutes 
        12. Others
      5. Canada
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
        4. Medication 
        5. Surgery 
        6. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        7. Plasmapheresis and Intravenous Immunoglobulin 
        8. Others
        9. Hospitals 
        10. Clinics 
        11. Academic Research Institutes 
        12. Others
    2. Europe
      1. Europe Myasthenia Gravis Treatment Market By Type 2022-2034 (USD MILLION/ Units)
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
      2. Europe Myasthenia Gravis Treatment Market By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication 
        2. Surgery 
        3. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        4. Plasmapheresis and Intravenous Immunoglobulin 
        5. Others
      3. Europe Myasthenia Gravis Treatment Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals 
        2. Clinics 
        3. Academic Research Institutes 
        4. Others
      4. U.K.
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
        4. Medication 
        5. Surgery 
        6. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        7. Plasmapheresis and Intravenous Immunoglobulin 
        8. Others
        9. Hospitals 
        10. Clinics 
        11. Academic Research Institutes 
        12. Others
      5. Germany
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
        4. Medication 
        5. Surgery 
        6. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        7. Plasmapheresis and Intravenous Immunoglobulin 
        8. Others
        9. Hospitals 
        10. Clinics 
        11. Academic Research Institutes 
        12. Others
      6. France
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
        4. Medication 
        5. Surgery 
        6. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        7. Plasmapheresis and Intravenous Immunoglobulin 
        8. Others
        9. Hospitals 
        10. Clinics 
        11. Academic Research Institutes 
        12. Others
      7. Spain
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
        4. Medication 
        5. Surgery 
        6. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        7. Plasmapheresis and Intravenous Immunoglobulin 
        8. Others
        9. Hospitals 
        10. Clinics 
        11. Academic Research Institutes 
        12. Others
      8. Italy
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
        4. Medication 
        5. Surgery 
        6. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        7. Plasmapheresis and Intravenous Immunoglobulin 
        8. Others
        9. Hospitals 
        10. Clinics 
        11. Academic Research Institutes 
        12. Others
      9. Russia
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
        4. Medication 
        5. Surgery 
        6. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        7. Plasmapheresis and Intravenous Immunoglobulin 
        8. Others
        9. Hospitals 
        10. Clinics 
        11. Academic Research Institutes 
        12. Others
      10. Nordic
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
        4. Medication 
        5. Surgery 
        6. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        7. Plasmapheresis and Intravenous Immunoglobulin 
        8. Others
        9. Hospitals 
        10. Clinics 
        11. Academic Research Institutes 
        12. Others
      11. Benelux
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
        4. Medication 
        5. Surgery 
        6. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        7. Plasmapheresis and Intravenous Immunoglobulin 
        8. Others
        9. Hospitals 
        10. Clinics 
        11. Academic Research Institutes 
        12. Others
      12. Rest of Europe
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
        4. Medication 
        5. Surgery 
        6. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        7. Plasmapheresis and Intravenous Immunoglobulin 
        8. Others
        9. Hospitals 
        10. Clinics 
        11. Academic Research Institutes 
        12. Others
    3. APAC
      1. APAC Myasthenia Gravis Treatment Market By Type 2022-2034 (USD MILLION/ Units)
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
      2. APAC Myasthenia Gravis Treatment Market By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication 
        2. Surgery 
        3. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        4. Plasmapheresis and Intravenous Immunoglobulin 
        5. Others
      3. APAC Myasthenia Gravis Treatment Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals 
        2. Clinics 
        3. Academic Research Institutes 
        4. Others
      4. China
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
        4. Medication 
        5. Surgery 
        6. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        7. Plasmapheresis and Intravenous Immunoglobulin 
        8. Others
        9. Hospitals 
        10. Clinics 
        11. Academic Research Institutes 
        12. Others
      5. Korea
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
        4. Medication 
        5. Surgery 
        6. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        7. Plasmapheresis and Intravenous Immunoglobulin 
        8. Others
        9. Hospitals 
        10. Clinics 
        11. Academic Research Institutes 
        12. Others
      6. Japan
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
        4. Medication 
        5. Surgery 
        6. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        7. Plasmapheresis and Intravenous Immunoglobulin 
        8. Others
        9. Hospitals 
        10. Clinics 
        11. Academic Research Institutes 
        12. Others
      7. India
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
        4. Medication 
        5. Surgery 
        6. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        7. Plasmapheresis and Intravenous Immunoglobulin 
        8. Others
        9. Hospitals 
        10. Clinics 
        11. Academic Research Institutes 
        12. Others
      8. Australia
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
        4. Medication 
        5. Surgery 
        6. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        7. Plasmapheresis and Intravenous Immunoglobulin 
        8. Others
        9. Hospitals 
        10. Clinics 
        11. Academic Research Institutes 
        12. Others
      9. Singapore
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
        4. Medication 
        5. Surgery 
        6. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        7. Plasmapheresis and Intravenous Immunoglobulin 
        8. Others
        9. Hospitals 
        10. Clinics 
        11. Academic Research Institutes 
        12. Others
      10. Taiwan
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
        4. Medication 
        5. Surgery 
        6. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        7. Plasmapheresis and Intravenous Immunoglobulin 
        8. Others
        9. Hospitals 
        10. Clinics 
        11. Academic Research Institutes 
        12. Others
      11. South East Asia
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
        4. Medication 
        5. Surgery 
        6. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        7. Plasmapheresis and Intravenous Immunoglobulin 
        8. Others
        9. Hospitals 
        10. Clinics 
        11. Academic Research Institutes 
        12. Others
      12. Rest of Asia-Pacific
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
        4. Medication 
        5. Surgery 
        6. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        7. Plasmapheresis and Intravenous Immunoglobulin 
        8. Others
        9. Hospitals 
        10. Clinics 
        11. Academic Research Institutes 
        12. Others
    4. Middle East and Africa
      1. Middle East and Africa Myasthenia Gravis Treatment Market By Type 2022-2034 (USD MILLION/ Units)
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
      2. Middle East and Africa Myasthenia Gravis Treatment Market By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication 
        2. Surgery 
        3. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        4. Plasmapheresis and Intravenous Immunoglobulin 
        5. Others
      3. Middle East and Africa Myasthenia Gravis Treatment Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals 
        2. Clinics 
        3. Academic Research Institutes 
        4. Others
      4. UAE
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
        4. Medication 
        5. Surgery 
        6. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        7. Plasmapheresis and Intravenous Immunoglobulin 
        8. Others
        9. Hospitals 
        10. Clinics 
        11. Academic Research Institutes 
        12. Others
      5. Turkey
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
        4. Medication 
        5. Surgery 
        6. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        7. Plasmapheresis and Intravenous Immunoglobulin 
        8. Others
        9. Hospitals 
        10. Clinics 
        11. Academic Research Institutes 
        12. Others
      6. Saudi Arabia
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
        4. Medication 
        5. Surgery 
        6. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        7. Plasmapheresis and Intravenous Immunoglobulin 
        8. Others
        9. Hospitals 
        10. Clinics 
        11. Academic Research Institutes 
        12. Others
      7. South Africa
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
        4. Medication 
        5. Surgery 
        6. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        7. Plasmapheresis and Intravenous Immunoglobulin 
        8. Others
        9. Hospitals 
        10. Clinics 
        11. Academic Research Institutes 
        12. Others
      8. Egypt
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
        4. Medication 
        5. Surgery 
        6. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        7. Plasmapheresis and Intravenous Immunoglobulin 
        8. Others
        9. Hospitals 
        10. Clinics 
        11. Academic Research Institutes 
        12. Others
      9. Nigeria
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
        4. Medication 
        5. Surgery 
        6. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        7. Plasmapheresis and Intravenous Immunoglobulin 
        8. Others
        9. Hospitals 
        10. Clinics 
        11. Academic Research Institutes 
        12. Others
      10. Rest of MEA
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
        4. Medication 
        5. Surgery 
        6. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        7. Plasmapheresis and Intravenous Immunoglobulin 
        8. Others
        9. Hospitals 
        10. Clinics 
        11. Academic Research Institutes 
        12. Others
    5. LATAM
      1. LATAM Myasthenia Gravis Treatment Market By Type 2022-2034 (USD MILLION/ Units)
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
      2. LATAM Myasthenia Gravis Treatment Market By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication 
        2. Surgery 
        3. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        4. Plasmapheresis and Intravenous Immunoglobulin 
        5. Others
      3. LATAM Myasthenia Gravis Treatment Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals 
        2. Clinics 
        3. Academic Research Institutes 
        4. Others
      4. Brazil
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
        4. Medication 
        5. Surgery 
        6. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        7. Plasmapheresis and Intravenous Immunoglobulin 
        8. Others
        9. Hospitals 
        10. Clinics 
        11. Academic Research Institutes 
        12. Others
      5. Mexico
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
        4. Medication 
        5. Surgery 
        6. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        7. Plasmapheresis and Intravenous Immunoglobulin 
        8. Others
        9. Hospitals 
        10. Clinics 
        11. Academic Research Institutes 
        12. Others
      6. Argentina
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
        4. Medication 
        5. Surgery 
        6. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        7. Plasmapheresis and Intravenous Immunoglobulin 
        8. Others
        9. Hospitals 
        10. Clinics 
        11. Academic Research Institutes 
        12. Others
      7. Chile
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
        4. Medication 
        5. Surgery 
        6. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        7. Plasmapheresis and Intravenous Immunoglobulin 
        8. Others
        9. Hospitals 
        10. Clinics 
        11. Academic Research Institutes 
        12. Others
      8. Colombia
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
        4. Medication 
        5. Surgery 
        6. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        7. Plasmapheresis and Intravenous Immunoglobulin 
        8. Others
        9. Hospitals 
        10. Clinics 
        11. Academic Research Institutes 
        12. Others
      9. Rest of LATAM
        1. Ocular MG 
        2. Congenital MG 
        3. Transient Neonatal MG
        4. Medication 
        5. Surgery 
        6. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
        7. Plasmapheresis and Intravenous Immunoglobulin 
        8. Others
        9. Hospitals 
        10. Clinics 
        11. Academic Research Institutes 
        12. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.